SAKAR2024-01-012024-03-31 SAKAR2024-01-012024-03-31 SAKAR2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SAKAR2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member SAKAR2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SAKAR NOTLISTED Sakar Healthcare Limited Equity 2023-04-01 2024-03-31 2024-05-21 2024-05-14 INR Lakhs Yearly 11:00:00 12:15:00 2024-05-21 2024-05-21 true Cash Flow Indirect Declaration of unmodified opinion Single segment Manufacturing Of Pharmaceutical Products 2024-01-01 2024-03-31 Audited Standalone 430588000.00 7678000.00 438266000.00 259455000.00 0.00 -10276000.00 51954000.00 20759000.00 48655000.00 19769000.00 390316000.00 47950000.00 0.00 47950000.00 0.00 16743000.00 16743000.00 0.00 31207000.00 0.00 0.00 0.00 0.00 31207000.00 528000.00 31735000.00 31735000.00 0.00 217499000.00 10 1.46 1.45 0.00 0.00 1.46 1.45 1 The figures for quarter ended on 31st March, 2024 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2024 and the year to date figures upto the third quarter of the financial year. 2 The Company is operating only in one segment i.e. Manufacturing Of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given. 3 The Company has a wholly owned subsidiary viz. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/associate. 4 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 5 Figures, wherever required, are regrouped/ rearranged. There are no material adjustments made in the results of the earlier periods. 6 The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 21st May, 2024 7 The Statutory Auditors have carried out an audit of the above results for the financial year ended 31st March, 2024 and have issued an unmodified opinion on the same. Single segment 2023-04-01 2024-03-31 Audited Standalone 1533517000.00 31771000.00 1565288000.00 850542000.00 0.00 -13767000.00 197838000.00 75905000.00 180505000.00 115268000.00 1406291000.00 158997000.00 0.00 158997000.00 0.00 42288000.00 42288000.00 0.00 116709000.00 0.00 0.00 0.00 0.00 116709000.00 -1069000.00 115640000.00 115640000.00 0.00 217499000.00 10 2357811000.00 5.64 5.63 0.00 0.00 5.64 5.63 Other expenses 19769000.00 Other expenses 115268000.00 3128297000.00 3155000.00 0.00 0.00 14572000.00 0.00 0.00 0.00 100000.00 0.00 3006000.00 0.00 3106000.00 0.00 21432000.00 3170562000.00 277323000.00 2077000.00 209126000.00 2559000.00 0.00 772000.00 0.00 214534000.00 0.00 225024000.00 716881000.00 0.00 0.00 3887443000.00 217499000.00 2406664000.00 2624163000.00 2624163000.00 549550000.00 0.00 0.00 549550000.00 22881000.00 100246000.00 0.00 0.00 672677000.00 138800000.00 274534000.00 105167000.00 518501000.00 57792000.00 1950000.00 12360000.00 0.00 590603000.00 0.00 0.00 1263280000.00 3887443000.00 66446000.00 -123348000.00 11485000.00 0.00 -75713000.00 0.00 0.00 2830000.00 0.00 13654000.00 0.00 26139000.00 0.00 180504000.00 0.00 7318000.00 146000.00 8633000.00 0.00 0.00 0.00 0.00 576000.00 0.00 0.00 -1481000.00 0.00 0.00 0.00 117189000.00 276186000.00 0.00 0.00 0.00 31519000.00 0.00 244667000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 595602000.00 31351000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48859000.00 0.00 -515392000.00 0.00 0.00 726199000.00 48000000.00 0.00 0.00 0.00 0.00 0.00 432730000.00 0.00 0.00 0.00 66446000.00 0.00 -576000.00 274447000.00 3722000.00 0.00 3722000.00 913000.00 4635000.00 731000.00 -1480000.00 203000.00 -411000.00 0.00 0.00